{"analyses":[{"ciLowerLimit":"0.87","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.42","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis: The stratification factors used in the analysis are axillary nodal status, surgery (breast conserving vs. mastectomy),and tumor PD-L1 status.","nonInferiorityType":"SUPERIORITY","pValue":"0.3846","paramType":"Hazard Ratio (HR)","paramValue":"1.11","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI for iDFS were not estimable due to too few events having occurred.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI for iDFS were not estimable due to too few events having occurred.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1098"},{"groupId":"OG001","value":"1101"}],"units":"Participants"}],"description":"iDFS was defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer involving the same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive breast cancer recurrence (an invasive breast cancer in the axilla, regional lymph nodes, chest wall, \\&/or skin of the ipsilateral breast); Ipsilateral second primary invasive breast cancer; Contralateral invasive breast cancer; Distant recurrence (evidence of breast cancer in any anatomic site \\[other than the sites mentioned\\]) that has either been histologically confirmed \\&/or clinically/radiographically diagnosed as recurrent invasive breast cancer; \\& Death attributable to any cause, including breast cancer, non-breast cancer, or unknown cause. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis or no post-baseline information were censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered paclitaxel, 80 mg/m\\^2, IV infusion QW for maximum of 36 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2 IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated every Q2W for a maximum of 20 weeks supported with G-CSF or GM-CSF treatment.","id":"OG000","title":"Chemotherapy"},{"description":"Participants were administered atezolizumab 840 mg, IV infusion, Q2W in combination with chemotherapy (paclitaxel 80 mg/m\\^2, IV infusion QW for maximum of 22 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2, IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated Q2W for maximum of 17 weeks supported with G-CSF or GM-CSF treatment followed by atezolizumab, 1200 mg IV infusion every Q3W as a maintenance therapy to complete 1 year of atezolizumab treatment from the first dose.","id":"OG001","title":"Atezolizumab and Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants, whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years)","title":"Invasive Disease-Free Survival (iDFS)","type":"PRIMARY","unitOfMeasure":"months"}